Pharmacological studies of a new 4 aminosugar cardiac glycoside (ASI 222)

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

ASI 222, 3β O (4 amino 4,6 dideoxy β (D) galactopyranosyl) digitoxigenin, is a semisynthetic cardiac glycoside patterned after a natural glycoside from Cambodia. Effects of ASI 222 on contractile force in the isolated rabbit atria, cardia contractile force, cardiac rate, ventricular excitability and functional refractory period in dogs, and acute toxicity in mice have been compared to those effects of ouabain. Both electrically driven and spontaneously beating atria demonstrated more rapid onset and greater maximum increases in contractile force with ASI 222 than with ouabain in equal bath concentrations. In the dog, ASI 222 increased cardiac contractile force more rapidly and at a lower cumulative dose than ouabain. Moreover, the maximum increase in contractile force obtained with ASI 222 was greater than that obtained with ouabain. The occurrence of ventricular ectopic beats was observed at a higher cumulative dose of ASI 222 than for ouabain. Also, ASI 222 produced a decrease in ventricular excitability and an increase in functional refractory period of the ventricle. Ouabain, in the same molar dose, produced either no change or a slight increase in these parameters. These data indicate that ASI 222 has a greater therapeutic index than ouabain. This difference may be partially explained by effects of ASI 222 on electrical properties of the heart.

Original languageEnglish (US)
Pages (from-to)19-26
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume197
Issue number1
StatePublished - Dec 1 1976
Externally publishedYes

Fingerprint

Cardiac Glycosides
Ouabain
Pharmacology
Digitoxigenin
Dogs
Cambodia
ASI-222
Cardia
Ventricular Premature Complexes
Glycosides
Baths
Rabbits

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pharmacological studies of a new 4 aminosugar cardiac glycoside (ASI 222). / Caldwell, Robert William; Nash, C. B.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 197, No. 1, 01.12.1976, p. 19-26.

Research output: Contribution to journalArticle

@article{df5a7c63c7614c13b28831159cd5d60d,
title = "Pharmacological studies of a new 4 aminosugar cardiac glycoside (ASI 222)",
abstract = "ASI 222, 3β O (4 amino 4,6 dideoxy β (D) galactopyranosyl) digitoxigenin, is a semisynthetic cardiac glycoside patterned after a natural glycoside from Cambodia. Effects of ASI 222 on contractile force in the isolated rabbit atria, cardia contractile force, cardiac rate, ventricular excitability and functional refractory period in dogs, and acute toxicity in mice have been compared to those effects of ouabain. Both electrically driven and spontaneously beating atria demonstrated more rapid onset and greater maximum increases in contractile force with ASI 222 than with ouabain in equal bath concentrations. In the dog, ASI 222 increased cardiac contractile force more rapidly and at a lower cumulative dose than ouabain. Moreover, the maximum increase in contractile force obtained with ASI 222 was greater than that obtained with ouabain. The occurrence of ventricular ectopic beats was observed at a higher cumulative dose of ASI 222 than for ouabain. Also, ASI 222 produced a decrease in ventricular excitability and an increase in functional refractory period of the ventricle. Ouabain, in the same molar dose, produced either no change or a slight increase in these parameters. These data indicate that ASI 222 has a greater therapeutic index than ouabain. This difference may be partially explained by effects of ASI 222 on electrical properties of the heart.",
author = "Caldwell, {Robert William} and Nash, {C. B.}",
year = "1976",
month = "12",
day = "1",
language = "English (US)",
volume = "197",
pages = "19--26",
journal = "The Journal of pharmacology and experimental therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Pharmacological studies of a new 4 aminosugar cardiac glycoside (ASI 222)

AU - Caldwell, Robert William

AU - Nash, C. B.

PY - 1976/12/1

Y1 - 1976/12/1

N2 - ASI 222, 3β O (4 amino 4,6 dideoxy β (D) galactopyranosyl) digitoxigenin, is a semisynthetic cardiac glycoside patterned after a natural glycoside from Cambodia. Effects of ASI 222 on contractile force in the isolated rabbit atria, cardia contractile force, cardiac rate, ventricular excitability and functional refractory period in dogs, and acute toxicity in mice have been compared to those effects of ouabain. Both electrically driven and spontaneously beating atria demonstrated more rapid onset and greater maximum increases in contractile force with ASI 222 than with ouabain in equal bath concentrations. In the dog, ASI 222 increased cardiac contractile force more rapidly and at a lower cumulative dose than ouabain. Moreover, the maximum increase in contractile force obtained with ASI 222 was greater than that obtained with ouabain. The occurrence of ventricular ectopic beats was observed at a higher cumulative dose of ASI 222 than for ouabain. Also, ASI 222 produced a decrease in ventricular excitability and an increase in functional refractory period of the ventricle. Ouabain, in the same molar dose, produced either no change or a slight increase in these parameters. These data indicate that ASI 222 has a greater therapeutic index than ouabain. This difference may be partially explained by effects of ASI 222 on electrical properties of the heart.

AB - ASI 222, 3β O (4 amino 4,6 dideoxy β (D) galactopyranosyl) digitoxigenin, is a semisynthetic cardiac glycoside patterned after a natural glycoside from Cambodia. Effects of ASI 222 on contractile force in the isolated rabbit atria, cardia contractile force, cardiac rate, ventricular excitability and functional refractory period in dogs, and acute toxicity in mice have been compared to those effects of ouabain. Both electrically driven and spontaneously beating atria demonstrated more rapid onset and greater maximum increases in contractile force with ASI 222 than with ouabain in equal bath concentrations. In the dog, ASI 222 increased cardiac contractile force more rapidly and at a lower cumulative dose than ouabain. Moreover, the maximum increase in contractile force obtained with ASI 222 was greater than that obtained with ouabain. The occurrence of ventricular ectopic beats was observed at a higher cumulative dose of ASI 222 than for ouabain. Also, ASI 222 produced a decrease in ventricular excitability and an increase in functional refractory period of the ventricle. Ouabain, in the same molar dose, produced either no change or a slight increase in these parameters. These data indicate that ASI 222 has a greater therapeutic index than ouabain. This difference may be partially explained by effects of ASI 222 on electrical properties of the heart.

UR - http://www.scopus.com/inward/record.url?scp=0017295488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017295488&partnerID=8YFLogxK

M3 - Article

VL - 197

SP - 19

EP - 26

JO - The Journal of pharmacology and experimental therapeutics

JF - The Journal of pharmacology and experimental therapeutics

SN - 0022-3565

IS - 1

ER -